NanoViricides, Inc. (NNVC)
| Market Cap | 36.25M +25.4% |
| Revenue (ttm) | n/a |
| Net Income | -8.22M |
| EPS | -0.41 |
| Shares Out | 25.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,408 |
| Open | 1.360 |
| Previous Close | 1.350 |
| Day's Range | 1.360 - 1.400 |
| 52-Week Range | 0.850 - 2.230 |
| Beta | 1.83 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+322.54%) |
| Est. Earnings | Nov 17, 2026 |
About NNVC
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NNVC stock is "Strong Buy." The 12-month stock price target is $6.0, which is an increase of 322.54% from the latest price.
News
NanoViricides says Phase IIa trial of NV-387 in ebola ‘progressing well’
NanoViricides (NNVC) explained that the Phase IIA Ebola Treatment Clinical Trial of NV-387 Oral Gummies is progressing well, and the drug is expected to advance into the Phase IIB clinical…
NanoViricides says NV-387 demonstrates ‘strong’ parameters in animal model study
NanoViricides (NNVC) announces that its broad-spectrum antiviral drug NV-387 has successfully demonstrated strong safety, tolerability, and toxicological parameters in an animal model study involving ...
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
The Spreading Ebola Epidemic as well as Mpox Endemic in Africa Disproportionately Impact Children; The Measles Outbreaks Primarily Impact Children SHELTON, CT / ACCESS Newswire / October 20, 2026 / Na...
NanoViricides announces Phase IIA Ebola trial of NV-387 is progressing well
NanoViricides (NNVC) said that its Phase IIA Ebola Treatment Clinical Trial of NV-387 Oral Gummies is progressing well. The Phase IIA part of the clinical trial is designed to evaluate…
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
SHELTON, CT / ACCESS Newswire / October 13, 2026 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, said today...
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
SHELTON, CT / ACCESS Newswire / October 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("the Company") is pleased to announce that it will be presenting tomorrow October 7, 2026 at NIBA's 153rd In...
NanoViricides says Phase II trial of NV-387 in ebola ‘proceeding as designed’
NanoViricides (NNVC) provides additional details on its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic…
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
SHELTON, CT / ACCESS Newswire / October 5, 2026 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith pr...
NanoViricides ‘actively exploring’ additional required funding
The company said, “We reported that, as of June 30, 2026, we had cash and cash equivalent current assets balance of approximately $2.79M. In addition, we reported approximately $6.4M in…
NanoViricides reports FY26 EPS (41c) vs. (63c) last year
The company said, “In the fiscal year 2026, we have achieved a substantial level of accomplishments. We have focused on regulatory advancement of our broad spectrum antiviral drug NV- 387.
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
SHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June ...
NanoViricides says Phase II trial of NV-387 in ebola starts enrollment, dosing
NanoViricides (NNVC) announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of…
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announce...
NanoViricides begins Phase II trial of NV-387 in Monkeypox in DRC
NanoViricides (NNVC) announced that the Phase II Clinical Trial of the Company’s Novel Broad-Spectrum Antiviral Drug NV-387 as a Treatment for Monkeypox Virus Infection has begun with enrollment of fi...
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Ant...
NanoViricides to begin Phase II trial of NV-387 in ebola next week
NanoViricides (NNVC) announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of…
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announce...
NanoViricides announces registration of Phase II trial of NV-387 in ebolavirus
NanoViricides (NNVC) announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of…
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces...
NanoViricides provides updateon Measles Drug Treatment Program
The company said, “While CDC is reviewing the two recent measles-related fatalities in Pennsylvania, the total number of confirmed measles cases in the USA has reached 2,903 as of August…
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American: NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development...
NanoViricides registers to sell 2.52M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.52M shares of common stock. The company is not selling any…
NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’
NanoViricides (NNVC), announced that the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon…
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces th...
NanoViricides receives regulatory approval for Phase II trial of NV-387
NanoViricides (NNVC) received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses, from the…